Glimepiride/pioglitazone

Mouse PGD2S/Prostaglandin D2 Synthase, Brain ELISA Kit

Biochem/physiol Actions Group III/II metabotropic glutamate (mGluR) receptor antagonist. Features and Benefits This compound is featured on the Glutamate Receptors (G Protein Family) page of the Handbook of Receptor Classification and Signal

Mse A-Ckn IgY-AF647 0.1 mg

N-(4-Fluorophenyl)pyridin-2(1H)-one is a metabolite of Pirfenidone, a new drug to treat patients with kidney disease who have diabetes.

A metabolite of Pirfenidone, which is a new drug used in the treatment for patients with kidney disease who have diabetes.

NAEPA is a selective EDG-2 (LPA1) receptor agonist as well as LPA mimetic.

NAEPA is a selective EDG-2 (LPA1) receptor agonist as well as LPA mimetic.

NAEPA is a selective EDG-2 (LPA1) receptor agonist as well as LPA mimetic.

NAEPA is a selective EDG-2 (LPA1) receptor agonist as well as LPA mimetic.

NAEPA is a selective EDG-2 (LPA1) receptor agonist as well as LPA mimetic.

InformationNaftopidil (KT-611) is a selectiveα1-adrenergic receptorantagonist withKiof 3.7 nM, 20 nM, and 1.2 nM for α1a, α1b, and α1d, respectively, used for the treatment of benign prostatic hyperplasia.In vitroNaftopidil is selective for the

NCRW0005-F05 is a potent GPR139 antagonist with an IC 50 value of 0.21 μM. NCRW0005-F05 can be used to research diabetes, obesity and Parkinson's diseaseForm:SolidIC50&amp: Target:IC 50 : 0.21 μM (GPR139).